Assessment of Response to Thienopyridine in Japanese Population (ART-JP)

Assessment of Response to Thienopyridine in Japanese Population (ART-JP) - ART-JP

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000006336

Enrollment

300

Registered

2011-09-13

Start date

2010-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery disease (CAD)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients receiving PCI and newly administered thienopyridine

Exclusion criteria

Exclusion criteria: 1) patients without consent 2) AST > or = 3 x upper limit or ALT > or = 3 x upper 3) Hb < 10 g/dl or platelet < 100k 4) drug allergy to thienopyridine 5) patients with malignancy under treatment or planning to start treatment within one year 6) primary physician thinks it is inappropriate to enroll the patient

Design outcomes

Primary

Measure	Time frame
cardiac death, fatal stroke, non-fatal myocardial infarction, stent thrombosis	—

Secondary

Measure	Time frame
repeat PCI, non cardiovasular death, non-fatal stroke, non-fatal cerebral hemorrhage, bleeding (STEEPLE major or minor), change in bio-marker	—

Countries

Japan

Contacts

Public ContactKenji Yokoyama

Keio University, School of Meidicine Division of Hematology, Department of Medicine

keyokoya@sc.itc.keio.ac.jp81-3-3353-1211

Outcome results